Anti-Inflammatory Drug and Endothelial Function

• Status: Unknown status
• Trial end date: 2020-06-30
• Target enrollment: 0
• Participant gender: All

Summary

In this randomized double-blinded clinical trial, 400mg of hydroxychloroquine will be given daily to people over the age of 65 years with moderate-severe obstructive sleep apnea for 8 weeks. The aim of this study is to test whether hydroxychloroquine can improve endothelial function.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Instituto de Cardiologia do Rio Grande do Sul
• Collaborator: Hospital de Clinicas de Porto Alegre
• Treatments: Hydroxychloroquine

Criteria

Inclusion Criteria:

• Apnea-Hypopnea index of 15 events/hour or higher

Exclusion Criteria:

• Contraindication for hydroxychloroquine (retinopathy, chronic liver disease, chronic renal disease)

• Rheumatologic disease